Maternal-fetal and neonatal pharmacogenomics: A review of current literature

Journal of Perinatology

Volumn 30, Issue 9, 2010, Pages 571-579

  Blumenfeld, Y J ^a   Reynolds May, M F ^b   Altman, R B ^c   El Sayed, Y Y ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ALCOHOL DEHYDROGENASE; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; CITALOPRAM; CODEINE; CYTOCHROME P450; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GLUTATHIONE TRANSFERASE M1; INDOMETACIN; INTERLEUKIN 6; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; NICOTINE; NIFEDIPINE; NITRIC OXIDE; OPIATE DERIVATIVE; PARACETAMOL; PAROXETINE; PHENAZONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAMADOL; UNINDEXED DRUG; VENLAFAXINE; WARFARIN;

AGITATION; ALCOHOLISM; CHORIOAMNIONITIS; CONGENITAL MALFORMATION; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; EMBRYO DEVELOPMENT; EMBRYOPATHY; FETAL HEMORRHAGE; FETOTOXICITY; FETUS DEVELOPMENT; FETUS OUTCOME; GASTROINTESTINAL SYMPTOM; GASTROSCHISIS; GENETIC VARIABILITY; GENOTOXICITY; HUMAN; HYPERTENSION; INSOMNIA; MAJOR DEPRESSION; NAUSEA; NEUROBLASTOMA; NEWBORN DISEASE; NEWBORN SEPSIS; PHARMACOGENOMICS; PLACENTA DEVELOPMENT; PREECLAMPSIA; PROTEIN FUNCTION; PROTEIN VARIANT; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TERATOGENICITY; TOBACCO DEPENDENCE; WEIGHT GAIN;

ANALGESICS, OPIOID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG TOXICITY; FEMALE; FETAL DEVELOPMENT; HUMANS; INFANT, NEWBORN; METABOLIC DETOXICATION, DRUG; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SEPSIS; SEROTONIN UPTAKE INHIBITORS; TERATOGENS;

EID: 77956253956     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2009.183     Document Type: Review

References (44)

1. Leeder JS. Developmental and pediatric pharmacogenomics. Pharmacogenomics 2003; 4: 331-341.
2. Sadee W. Drug therapy and personalized health care: pharmacogenomics in perspective. Pharm Res 2008; 25: 2713-2719.
3. Shurin SB, Nabel EG. PharmacogenomicsFready for prime time? N Engl J Med 2008; 358: 1061-1063.
4. Cunningham FG, Williams JW. Williams Obstetrics. McGraw-Hill: New York, 2001.
5. Sadler TW, Langman J. Langmans Medical Embryology. Lippincott Williams & Wilkins: Philadelphia, 2006.
6. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980; 68: 122-140.
7. Bieche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 2007; 17: 731-742.
8. Hakkola J, Pelkonen O, Pasanen M, Raunio H. Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity. Crit Rev Toxicol 1998; 28: 35-72.
9. Wang L, Weinshilboum RM. Pharmacogenomics: candidate gene identification, functional validation and mechanisms. Hum Mol Genet 2008; 17: R174-R179.
10. Hoyert DL, Mathews TJ, Menacker F, Strobino DM, Guyer B. Annual summary of vital statistics: 2004. Pediatrics 2006; 117: 168-183.
11. Yoon PW, Olney RS, Khoury MJ, Sappenfield WM, Chavez GF, Taylor D. Contribution of birth defects and genetic diseases to pediatric hospitalizations. A population-based study. Arch Pediatr Adolesc Med 1997; 151: 1096-1103.
12. Leeder JS, Mitchell AA. Application of pharmacogenomic strategies to the study of druginduced birth defects. Clin Pharmacol Ther 2007; 81: 595-599.
13. Boyle CA, Decoufle P, Yeargin-Allsopp M. Prevalence and health impact of developmental disabilities in US children. Pediatrics 1994; 93: 399-403.
14. Gaedigk A, Baker DW, Totah RA, Gaedigk R, Pearce RE, Vyhlidal CA et al. Variability of CYP2J2 expression in human fetal tissues. J Pharmacol Exp Ther 2006; 319: 523-532.
15. Adjei AA, Gaedigk A, Simon SD, Weinshilboum RM, Leeder JS. Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol 2008; 82: 155-165.
16. Richard K, Hume R, Kaptein E, Stanley EL, Visser TJ, Coughtrie MW. Sulfation of thyroid hormone and dopamine during human development: ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung, and brain. J Clin Endocrinol Metab 2001; 86: 2734-2742.
17. Vietri M, Pietrabissa A, Mosca F, Rane A, Pacific GM. Human adult and foetal liver sulphotransferases: inhibition by mefenamic acid and salicylic acid. Xenobiotica 2001; 31: 153-161.
18. Barker EV, Hume R, Hallas A, Coughtrie WH. Dehydroepiandrosterone sulfotransferase in the developing human fetus: quantitative biochemical and immunological characterization of the hepatic, renal, and adrenal enzymes. Endocrinology 1994; 134: 982-989.
19. Duanmu Z, Weckle A, Koukouritaki SB, Hines RN, Falany JL, Falany CN et al. Developmental expression of aryl, estrogen, and hydroxysteroid sulfotransferases in pre-and postnatal human liver. J Pharmacol Exp Ther 2006; 316: 1310-1317.
20. Rodriguez-Antona C, Jande M, Rane A, Ingelman-Sundberg M. Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. Clin Pharmacol Ther 2005; 77: 259-270.
21. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004; 351: 2827-2831.
22. Cascorbi I. Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. Eur J Clin Invest 2003; 33(Suppl 2): 17-22.
23. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368: 704.
24. Allegaert K, Van Den Anker JN, Verbesselt R, de Hoon J, Vanhole C, Tibboel D et al. O-demethylation of tramadol in the first months of life. Eur J Clin Pharmacol 2005; 61: 837-842.
25. Allegaert K, Van Schaik RH, Vermeersch S, Verbesselt R, Cossey V, Vanhole C et al. Postmenstrual age and CYP2D6 polymorphisms determine tramadol O-demethylation in critically ill neonates and infants. Pediatr Res 2008; 63: 674-679.
26. Madadi P, Ross C, Hayden M, Carleton BC, Gaedigk A, Leeder JS et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 2008; 85: 31-35.
27. Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 2005; 106: 1071-1083.
28. Mann JJ. The medical management of depression. N Engl J Med 2005; 353: 1819-1834.
29. Ferreira E, Carceller AM, Agogue C, Martin BZ, St-Andre M, Francoeur D et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 2007; 119: 52-59.
30. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 579-587.
31. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63: 898-906.
32. Oberlander TF, Bonaguro RJ, Misri S, Papsdorf M, Ross CJ, Simpson EM. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 2008; 13: 65-73.
33. Berle JO, Steen VM, Aamo TO, Breilid H, Zahlsen K, Spigset O. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. J Clin Psychiatry 2004; 65: 1228-1234.
34. Carcillo JA, Doughty L, Kofos D, Frye RF, Kaplan SS, Sasser H et al. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med 2003; 29: 980-984.
35. Del Vecchio A, Laforgia N, Capasso M, Iolascon A, Latini G. The role of molecular genetics in the pathogenesis and diagnosis of neonatal sepsis. Clin Perinatol 2004; 31: 53-67.
36. Nebert DW, Mckinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 1996; 15: 273-280.
37. Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 2003; 17: 27-41.
38. Joseph T, Kusumakumary P, Chacko P, Abraham A, Radhakrishna Pillai M. Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children. Pediatr Blood Cancer 2004; 43: 560-567.
39. Ashton LJ, Murray JE, Haber M, Marshall GM, Ashley DM, Norris MD. Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma. Pharmacogenet Genomics 2007; 17: 709-717.
40. Creasy RK, Resnick R. Maternal-Fetal Medicine. Saunders: Philadelphia, 2004.
41. Wall TM, Schoedel K, Ring HZ, Luczak SE, Katsuyoshi DM, Tyndale RF. Differences in pharmacogenetics of nicotine and alcohol metabolism: review and recommendations for future research. Nicotine Tob Res 2007; 9(Suppl 3): S459-S474.
42. Van Dyke DC, Hodge SE, Heide F, Hill LR. Family studies in fetal phenytoin exposure. J Pediatr 1988; 113: 301-306.
43. International Warfarin Pharmacogenetics Consortium Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
44. Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci USA 2008; 105: 16266-16271.